药物联合化疗失败及其引发的侵袭性真菌感染已成为肿瘤患者致死的两大重要原因。申请人聚焦于这两个关键环节，在基础研究和新药研发方面完成了系统工作，为化学治疗提供了全新药物干预策略。主要贡献：（1）建立了基于靶标精准药物设计和基于多样性化合物库构建及表型筛选的新药发现技术；（2）基于吴茱萸碱和p53-MDM2蛋白-蛋白相互作用获得了具有全新多靶点作用机制的抗肿瘤候选新药；（3）研发化药1.1类抗真菌创新药艾迪康唑完成 III 期临床试验，并发现了3类具有原创性的抗耐药先导物。以第一或通讯作者在 J. Med. Chem.（11篇）等期刊发表 SCI 文章92篇（近5 年55篇，22篇IF>5)。入选国家优青、青年长江学者等14项省部级以上人才计划，获得国家科技进步二等奖（2015-5）等15项奖励。拟针对“真菌感染耐药性严重”这一重要科学问题，基于新靶点和新分子骨架开展抗耐药真菌的新药发现研究。

Failure of combinational drug chemotherapy and its following induced invasive fungal infections are two major causes that lead to high mortality of cancer patients. My research focuses on these two key factors and completed systemic works in both basic medicinal chemistry research and new drug development, which provides novel drug intervention strategies for chemotherapy. My academic contributions mainly include: (1) the development of several new technologies for target-based rational drug design and phenotypic screening-based construction of diverse compound libraries; (2) the discovery of novel multi-targeting antitumor candidate drugs with new mode of actions on the basis of evodimaine and p53-MDM2 protein-protein interaction; (3) the development of iodiconazole as an antifungal new drug (phase III clinical trial completed) and the discovery of three classes of innovative antifungal lead compounds for the treatment of resistant infections. As the first author or corresponding author, I have published 92 SCI papers (55 in recent 5 years, 22 papers IF > 5) including 11 JMC articles. I was supported by 14 talent programs including National Excellent Young Scholarship (NSFC) and Young Yangtse Rive Scholar (MOE). I won 15 academic awards such as “Second Class Prize of The State Scientific and Technological Progress Award”. To address the resistance problem of fungal infections, my research plan will mainly focus on the new antifungal drug discovery based on new molecular scaffolds and new targets.